BAVARIAN NORDIC
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1992-01-01
- Employees
- 759
- Market Cap
- $3.1B
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®
- Conditions
- 18-42 Year Old Healthy Vaccinia-naïve Subjects
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 440
- Registration Number
- NCT01913353
- Locations
- 🇰🇷
Brian Allgood Army Community Hospital, Seoul, Korea, Republic of
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
- Conditions
- Cholera
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 197
- Registration Number
- NCT01895855
- Locations
- 🇺🇸
University of Maryland Baltimore, Baltimore, Maryland, United States
🇺🇸Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Vermont, Burlington, Vermont, United States
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
- Conditions
- Smallpox
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 651
- Registration Number
- NCT01668537
- Locations
- 🇺🇸
Miami Research Associates, South Miami, Florida, United States
🇺🇸PRA, Lenexa, Kansas, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200
- Conditions
- Cholera
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 66
- Registration Number
- NCT01585181
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
- Conditions
- Prostate Cancer Metastatic
- Interventions
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 1297
- Registration Number
- NCT01322490
- Locations
- 🇺🇸
Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States
🇺🇸Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
- Conditions
- Breast Cancer
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 15
- Registration Number
- NCT01152398
- Locations
- 🇺🇸
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
- Conditions
- Smallpox
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 4005
- Registration Number
- NCT01144637
- Locations
- 🇺🇸
Alabama Vaccine Research Clinic, Birmingham, Alabama, United States
🇺🇸Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸National Research Institute, Los Angeles, California, United States
Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years
- Conditions
- Measles
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 90
- Registration Number
- NCT00891007
- Locations
- 🇿🇦
Chris Hani Baragwanath Hospital, Respiratory and Meningeal Pathogens Research Unit, Bertsham, South Africa
A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects
- Conditions
- Smallpox
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 120
- Registration Number
- NCT00857493
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸University of Kentucky, School of Medicine, Department of Medicine, Lexington, Kentucky, United States
An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees
- Conditions
- Smallpox
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 304
- Registration Number
- NCT00686582
- Locations
- 🇩🇪
Harrison Clinical Research Deutschland GmbH, München, Germany